These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 31208693)

  • 1. Dual Targeting of Autophagy and MEK in KRAS Mutant Cancer.
    Zhao H; Zheng B
    Trends Cancer; 2019 Jun; 5(6):327-329. PubMed ID: 31208693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.
    Bryant KL; Stalnecker CA; Zeitouni D; Klomp JE; Peng S; Tikunov AP; Gunda V; Pierobon M; Waters AM; George SD; Tomar G; Papke B; Hobbs GA; Yan L; Hayes TK; Diehl JN; Goode GD; Chaika NV; Wang Y; Zhang GF; Witkiewicz AK; Knudsen ES; Petricoin EF; Singh PK; Macdonald JM; Tran NL; Lyssiotis CA; Ying H; Kimmelman AC; Cox AD; Der CJ
    Nat Med; 2019 Apr; 25(4):628-640. PubMed ID: 30833752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
    Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
    Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
    [No Abstract]   [Full Text] [Related]  

  • 4. Chloroquine and hydroxychloroquine inhibit bladder cancer cell growth by targeting basal autophagy and enhancing apoptosis.
    Lin YC; Lin JF; Wen SI; Yang SC; Tsai TF; Chen HE; Chou KY; Hwang TI
    Kaohsiung J Med Sci; 2017 May; 33(5):215-223. PubMed ID: 28433067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells.
    Lamba S; Russo M; Sun C; Lazzari L; Cancelliere C; Grernrum W; Lieftink C; Bernards R; Di Nicolantonio F; Bardelli A
    Cell Rep; 2014 Sep; 8(5):1475-83. PubMed ID: 25199829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
    Kuracha MR; Thomas P; Loggie BW; Govindarajan V
    PLoS One; 2017; 12(6):e0179510. PubMed ID: 28640835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
    Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
    EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting autophagy addiction of tumor cells.
    Nyfeler B; Eng CH
    Autophagy; 2016 Jul; 12(7):1206-7. PubMed ID: 27097231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy.
    Alves S; Castro L; Fernandes MS; Francisco R; Castro P; Priault M; Chaves SR; Moyer MP; Oliveira C; Seruca R; Côrte-Real M; Sousa MJ; Preto A
    Oncotarget; 2015 Oct; 6(31):30787-802. PubMed ID: 26418750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach.
    Yoon YK; Kim HP; Han SW; Oh DY; Im SA; Bang YJ; Kim TY
    Mol Carcinog; 2010 Apr; 49(4):353-62. PubMed ID: 20358631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
    Dogan Turacli I; Ozkan AC; Ekmekci A
    Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Approach of KRAS Mutant Tumours by the Combination of Pharmacologic Ascorbate and Chloroquine.
    Kapuy O; Makk-Merczel K; Szarka A
    Biomolecules; 2021 Apr; 11(5):. PubMed ID: 33925206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
    Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
    Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy.
    Eng CH; Wang Z; Tkach D; Toral-Barza L; Ugwonali S; Liu S; Fitzgerald SL; George E; Frias E; Cochran N; De Jesus R; McAllister G; Hoffman GR; Bray K; Lemon L; Lucas J; Fantin VR; Abraham RT; Murphy LO; Nyfeler B
    Proc Natl Acad Sci U S A; 2016 Jan; 113(1):182-7. PubMed ID: 26677873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
    Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
    Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
    Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
    Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells.
    Cheon SK; Kim HP; Park YL; Jang JE; Lim Y; Song SH; Han SW; Kim TY
    Mol Oncol; 2018 Aug; 12(8):1398-1409. PubMed ID: 29896883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers.
    Okumura S; Jänne PA
    Clin Cancer Res; 2014 Aug; 20(16):4193-9. PubMed ID: 24907112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway.
    Kochetkova EY; Blinova GI; Bystrova OA; Martynova MG; Pospelov VA; Pospelova TV
    Aging (Albany NY); 2017 Nov; 9(11):2352-2375. PubMed ID: 29140794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
    Dai X; Xia H; Zhou S; Tang Q; Bi F
    Cancer Lett; 2019 Feb; 442():202-212. PubMed ID: 30429107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.